GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2010

Evotec to Screen for Hits against Active Biotech Immune Disorder and Cancer Target

  • Evotec signed a high-throughput screening agreement with Active Biotech. The company is tasked with identifing and validating novel hits against an Active Biotech target involved in immune disorders and cancer.

    Screening will focus on Evotec’s own small molecule Lead Discovery Library. The firm will leverage its high-throughput screening and surface plasmon resonance screening capabilities.

    “We are impressed by the excellent quality of Evotec’s Lead Discovery Library, which we believe will enable us to generate high-quality hits, ensuring a smooth transition to medicinal chemistry activities,” comments Dorthe da Graça Trhige, Active Biotech’s director of development. “Importantly, the hits identified in the HTS will complement the ongoing lead optimization of compounds identified in house.”

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?